Table 1.
Keywords, GO terms and pathway enrichments after MgSO4 single injection (List A).
| Up_Keywords (David® v6.8 Analysis) | Count | p-Value * | Enrichment | FDR | |
| Synapse | 70 | 5.08 × 10−16 | 3.31 | 1.06 × 10−16 | |
| Neurogenesis | 48 | 3.56 × 10−10 | 3.28 | 3.73 × 10−11 | |
| Cell junction | 102 | 2.90 × 10−16 | 2.60 | 8.10 × 10−17 | |
| Methylation | 128 | 1.66 × 10−15 | 2.25 | 2.31 × 10−16 | |
| Golgi apparatus | 99 | 5.52 × 10−11 | 2.22 | 6.60 × 10−12 | |
| Cell projection | 82 | 5.09 × 10−7 | 2.04 | 3.55 × 10−8 | |
| GO Terms (David® analysis) | Count | p-Value * | Enrichment | FDR | Dispensability |
| GO:0045202~synapse | 91 | 2.69 × 10−16 | 2.80 | 1.87 × 10−9 | 0.00 |
| GO:0043005~neuron projection | 75 | 1.01 × 10−12 | 2.77 | 6.17 × 10−16 | 0.00 |
| GO:0014069~postsynaptic density | 49 | 8.14 × 10−10 | 3.18 | 2.32 × 10−12 | 0.04 |
| GO:0007399~nervous system development | 64 | 2.94 × 10−8 | 2.56 | 1.41 × 10−8 | 0.00 |
| GO:0048167~regulation of synaptic plasticity | 13 | 4.33 × 10−2 # | 4.68 | 2.12 × 10−12 | 0.14 |
| KEGG_Pathways (DAVID® analysis) | Count | p-Value * | Enrichment | FDR | |
| mmu04360:Axon guidance | 28 | 1.66 × 10−5 | 3.27 | 1.36 × 10−5 | |
| mmu04919:Thyroid hormone signaling pathway | 25 | 8.09 × 10−5 | 3.30 | 3.30 × 10−5 | |
| mmu04722:Neurotrophin signaling pathway | 24 | 1.08 × 10−3 | 2.96 | 2.41 × 10−4 | |
| mmu04024:cAMP signaling pathway | 32 | 1.34 × 10−3 | 2.44 | 2.41 × 10−4 | |
| mmu05200:Pathways in cancer | 51 | 1.48 × 10−3 | 1.94 | 2.41 × 10−4 | |
| mmu04910:Insulin signaling pathway | 24 | 4.19 × 10−5 # | 2.58 | 1.14 × 10−3 | |
| IPA Pathways (Ingenuity analysis) | Count | p-Value | N Max $ | Kinetics £ | z-score |
| Synaptogenesis Signaling Pathway | 40 | 4.79 × 10−9 | 6 h | L (4) | −5.667 |
| Reelin Signaling in Neurons | 19 | 3.16 × 10−5 | 6 h | L (2) | −4.000 |
| Axonal Guidance Signaling | 41 | 7.08 × 10−5 | 3 h–12 h | L (2) | ¤ |
| Signaling by Rho Family GTPases | 27 | 9.77 × 10−5 | 6 h | L (2) | −4.472 |
| Netrin Signaling | 12 | 1.00 × 10−4 | 6 h | L (3) | −3.317 |
| nNOS Signaling in Neurons | 11 | 1.12 × 10−4 | 3 h | L(2) | −2.236 |
| GNRH Signaling | 22 | 1.45 × 10−4 | 6 h | L(3) | −3.207 |
| Ephrin Receptor Signaling | 19 | 3.09 × 10−4 | 3 h–12 h | L (2) | −3.873 |
| Opioid Signaling Pathway | 25 | 3.63 × 10−4 | 6 h | E (1) | −3.130 |
| Endocannabinoid Neuronal Synapse Pathway | 16 | 4.68 × 10−4 | 6 h | E(1) | −2.324 |
| Corticotropin Releasing Hormone Signaling | 19 | 4.90 × 10−4 | 6 h | E(1) | −1.897 |
| Renin-Angiotensin Signaling | 17 | 5.01 × 10−4 | 6 h | L (3) | −3.464 |
| CREB Signaling in Neurons | 24 | 7.08 × 10−4 | 6 h | E (1) | −3.606 |
| PTEN Signaling | 15 | 8.128 × 10−3 | 12 h | L (0) | +2.714 |
DAVID® identifications of enriched KEGG pathways and Up_Keywords, based on 1411 genes. Selection of 5 nervous system-related seGO-terms exhibiting among the highest enrichments. IPA® determinations done on 1492 regulated probes exhibiting p-values < 1 × 10−3 at least at one time point, with the exception of PTEN signaling, the only seIPA with a positive z-score). * t-test p-value after Bonferroni correction (not for IPA analysis). $ Max indicates the time point exhibiting the maximum number of genes in the pathway. # italics indicate p-value according to Fisher exact test. £ Kinetics evaluated based on lowest IPA p-values (<1 × 10−3) were observed at 4 out of 5 time points (none at 24 h), noted as E (early) and L (lasting). Values in parentheses indicate the number of time points with p-values < 1 × 10−3). ¤ No z-score calculated.